Your browser is no longer supported. Please, upgrade your browser.
Settings
CYTX Cytori Therapeutics, Inc. daily Stock Chart
CYTX [NASD]
Cytori Therapeutics, Inc.
Index- P/E- EPS (ttm)-6.08 Insider Own16.00% Shs Outstand6.68M Perf Week-30.38%
Market Cap11.02M Forward P/E- EPS next Y-0.28 Insider Trans-52.59% Shs Float5.84M Perf Month-43.10%
Income-23.50M PEG- EPS next Q-0.46 Inst Own17.50% Short Float4.81% Perf Quarter-46.72%
Sales6.40M P/S1.72 EPS this Y35.40% Inst Trans4.38% Short Ratio3.96 Perf Half Y-36.54%
Book/sh1.41 P/B1.17 EPS next Y65.70% ROA-80.30% Target Price1.75 Perf Year-84.34%
Cash/sh0.88 P/C1.87 EPS next 5Y- ROE-232.20% 52W Range1.75 - 12.10 Perf YTD-45.29%
Dividend- P/FCF- EPS past 5Y36.90% ROI-77.80% 52W High-86.36% Beta3.10
Dividend %- Quick Ratio0.40 Sales past 5Y-15.10% Gross Margin62.70% 52W Low-5.71% ATR0.24
Employees80 Current Ratio0.60 Sales Q/Q0.00% Oper. Margin- RSI (14)25.52 Volatility8.05% 11.02%
OptionableYes Debt/Eq1.61 EPS Q/Q77.90% Profit Margin- Rel Volume1.22 Prev Close1.75
ShortableYes LT Debt/Eq0.00 EarningsMay 10 AMC Payout- Avg Volume70.87K Price1.65
Recom2.30 SMA20-32.08% SMA50-37.75% SMA200-50.84% Volume86,535 Change-5.71%
Feb-22-18Resumed Laidlaw Buy $1.65
Aug-11-17Reiterated Maxim Group Buy $10 → $5
Jul-25-17Downgrade B. Riley & Co. Buy → Neutral
Aug-10-15Reiterated ROTH Capital Buy $6 → $4
Jan-16-15Reiterated ROTH Capital Buy $3.50 → $6
Dec-11-14Reiterated Maxim Group Buy $4 → $6
Dec-10-14Reiterated Maxim Group Buy $4 → $6
May-13-14Reiterated Maxim Group Buy $10 → $9
Feb-20-13Initiated Ascendiant Capital Markets Buy $3.25
Sep-07-12Initiated Maxim Group Buy $10
Dec-21-09Downgrade Rodman & Renshaw Mkt Outperform → Mkt Perform
Nov-24-08Reiterated Rodman & Renshaw Mkt Perform $8 → $5
Jun-13-08Reiterated Stanford Research Buy $10 → $13
Jan-02-08Initiated Rodman & Renshaw Mkt Outperform $8
Dec-12-07Initiated Broadpoint Capital Buy
Oct-09-07Initiated Stanford Research Buy
Jun-14-07Initiated Piper Jaffray Market Perform $6
Jun-12-18 08:30AM  Cytori Informs Stockholders of Key Dates and Terms Related to Announced Rights Offering GlobeNewswire
May-25-18 03:37PM  Cytori Therapeutics Inc (NASDAQ:CYTX): Are Analysts Optimistic? Simply Wall St.
May-24-18 08:37AM  Benzinga's Daily Biotech Pulse: Eiger And Melinta Fall On Offerings, Apellis And Marinus Rise On Bullish Ratings Benzinga -8.88%
May-23-18 04:55PM  Cytori Therapeutics common stock to begin trading on adjusted basis on May 24, following one-for-ten reverse split GlobeNewswire -6.19%
May-18-18 08:19PM  Edited Transcript of CYTX earnings conference call or presentation 10-May-18 9:30pm GMT Thomson Reuters StreetEvents
05:33PM  SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Cytori Therapeutics, Inc. Business Wire
May-10-18 07:43PM  Cytori: 1Q Earnings Snapshot Associated Press +6.09%
04:25PM  Cytori Reports Q1 2018 Business and Financial Results GlobeNewswire
May-07-18 04:15PM  Cytori to Webcast First Quarter Financial Results on May 10 GlobeNewswire
Apr-30-18 08:30AM  Cytori Provides Update on US Manufacturing and EU Approval Plans for ATI-0918, Liposomal Doxorubicin GlobeNewswire
Mar-28-18 12:00PM  Enrollment Completed in ADRESU Clinical Trial of Cytori Cell Therapy for Stress Urinary Incontinence GlobeNewswire +5.77%
07:40AM  Blog Exposure - Biohaven Reported Positive Top-line Results For its Two Pivotal Phase-3 Trials of Rimegepant ACCESSWIRE
Mar-12-18 01:16PM  Edited Transcript of CYTX earnings conference call or presentation 8-Mar-18 10:30pm GMT Thomson Reuters StreetEvents
Mar-09-18 05:00AM  Cytori reports 4Q loss Associated Press
Mar-08-18 04:25PM  Cytori Reports Fourth Quarter and Full Year 2017 Business and Financial Results GlobeNewswire
01:39PM  Want To Invest In Cytori Therapeutics Inc (NASDAQ:CYTX)? Heres How It Performed Lately Simply Wall St.
09:24AM  Cytori Therapeutics Q4 Earnings Preview Benzinga
Feb-22-18 04:15PM  Cytori to Webcast Fourth Quarter Financial Results on March 8th GlobeNewswire +6.82%
Feb-15-18 08:00AM  Cytori Scleroderma Trial Data Presented at Systemic Sclerosis World Congress GlobeNewswire -8.03%
Feb-09-18 04:45PM  Cytori Therapeutics Announces Inducement Grants for New Employees GlobeNewswire -7.35%
Jan-22-18 09:00AM  Enrollment Completed in Randomized Clinical Trial of Habeo Cell Therapy for Scleroderma and Impaired Hand Function GlobeNewswire
Jan-05-18 05:20PM  Heres Why Cytori Therapeutics Inc (CYTX) Shares Skyrocketed Today SmarterAnalyst +73.75%
Dec-18-17 03:19PM  ETFs with exposure to Cytori Therapeutics, Inc. : December 18, 2017 Capital Cube
Dec-08-17 12:38PM  ETFs with exposure to Cytori Therapeutics, Inc. : December 8, 2017 Capital Cube
Nov-30-17 04:15PM  Cytori Therapeutics Incs (CYTX) Earnings Declined 36.4%, But How Did It Fare Against The Industry? Simply Wall St.
Nov-28-17 04:05PM  Cytori Closes Rights Offering for Gross Proceeds of $10 Million GlobeNewswire
Nov-27-17 01:03PM  ETFs with exposure to Cytori Therapeutics, Inc. : November 27, 2017 Capital Cube -7.42%
Nov-21-17 08:37AM  Cytori Therapeutics, Inc. :CYTX-US: Earnings Analysis: Q3, 2017 By the Numbers : November 21, 2017 Capital Cube -8.87%
Nov-20-17 09:41PM  Edited Transcript of CYTX earnings conference call or presentation 9-Nov-17 10:30pm GMT Thomson Reuters StreetEvents
09:00AM  Cytori Reports Reduction in Fibrosis Parameters in Scar Study GlobeNewswire
Nov-16-17 08:00AM  Cytori Reports Bioequivalence Trial Results in Ovarian Cancer at AAPS GlobeNewswire
Nov-15-17 08:00AM  Cytori Reminds Stockholders That Rights Offering Expires on Tuesday, November 21 GlobeNewswire -11.02%
Nov-13-17 09:00AM  Cytori Announces New U.S. Investigator Trial for Hip Osteonecrosis GlobeNewswire +5.57%
Nov-09-17 07:43PM  Cytori reports 3Q loss Associated Press
04:25PM  Cytori Reports Third Quarter 2017 Business and Financial Results GlobeNewswire
Nov-07-17 09:00AM  STAR Trial Data Accepted for Presentation at Systemic Sclerosis World Congress GlobeNewswire
Nov-06-17 11:24AM  ETFs with exposure to Cytori Therapeutics, Inc. : November 6, 2017 Capital Cube
Nov-02-17 08:00AM  Cytori to Webcast Third Quarter Financial Results on November 9 GlobeNewswire
Oct-26-17 10:26AM  ETFs with exposure to Cytori Therapeutics, Inc. : October 26, 2017 Capital Cube -9.45%
Oct-17-17 06:11PM  Should You Buy Cytori Therapeutics Inc (CYTX) Now? Simply Wall St.
Oct-09-17 11:27AM  ETFs with exposure to Cytori Therapeutics, Inc. : October 9, 2017 Capital Cube -14.95%
08:00AM  Today's Research Reports on Trending Tickers: Cytori Therapeutics and Repros Therapeutics ACCESSWIRE
Sep-27-17 10:27AM  ETFs with exposure to Cytori Therapeutics, Inc. : September 27, 2017 Capital Cube +5.51%
Sep-07-17 12:55PM  ETFs with exposure to Cytori Therapeutics, Inc. : September 7, 2017 Capital Cube
Sep-01-17 04:15PM  Cytori Announces Corporate Restructuring & Cost Reduction Plan GlobeNewswire
Aug-25-17 04:15PM  ETFs with exposure to Cytori Therapeutics, Inc. : August 25, 2017 Capital Cube +8.50%
Aug-17-17 09:26AM  Biotech Movers: Red Hill Jumps After Securing Rights Sell GERD Treatment TheStreet.com
Aug-16-17 08:16PM  Edited Transcript of CYTX earnings conference call or presentation 10-Aug-17 9:30pm GMT Thomson Reuters StreetEvents
09:44AM  Cytori Therapeutics, Inc. :CYTX-US: Earnings Analysis: Q2, 2017 By the Numbers : August 16, 2017 Capital Cube
Aug-10-17 10:04PM  Cytori reports 2Q loss Associated Press
04:30PM  Investor Network: Cytori Therapeutics, Inc. to Host Earnings Call ACCESSWIRE
04:25PM  Cytori Reports Second Quarter 2017 Business and Financial Results GlobeNewswire
Aug-04-17 04:05PM  Cytori to Webcast Second Quarter Financial Results on August 10 GlobeNewswire
Jul-25-17 04:30PM  Cytori Therapeutics Announces Inducement Grants for New Employees GlobeNewswire
08:00AM  Today's Research Reports on Stocks to Watch: Cytori Therapeutics and Novavax Accesswire
Jul-24-17 11:54AM  Analysts Remain Buyers of 2 Volatile Healthcare Stocks: Cytori Therapeutics Inc (CYTX) and TearLab Corp (TEAR) SmarterAnalyst -56.77%
08:00AM  Cytori Announces Top-Line 24- and 48-Week Results from the STAR Trial of Habeo Cell Therapy in Patients with Scleroderma GlobeNewswire
Jul-10-17 07:00AM  American Medical Association Approves New Category III CPT Codes Describing Cytoris Scleroderma Therapy GlobeNewswire
Jul-07-17 08:33AM  Are Options Traders Betting on a Big Move in Cytori Therapeutics (CYTX) Stock? Zacks
Jul-06-17 07:00AM  Cytori Receives Key Cell Therapy Patent for Scleroderma GlobeNewswire
Jul-05-17 12:37PM  ETFs with exposure to Cytori Therapeutics, Inc. : July 5, 2017 Capital Cube -6.48%
Jun-14-17 09:00AM  Cytori® Partners with myTomorrows for Managed Access Program for Europe, Middle East and Latin America GlobeNewswire -5.56%
Jun-08-17 07:00AM  Long Term Safety Data Published on Cytori Technology for Breast Reconstruction After Oncologic Surgery & Radiation Therapy GlobeNewswire
Jun-06-17 11:40AM  ETFs with exposure to Cytori Therapeutics, Inc. : June 6, 2017 Capital Cube
Jun-01-17 07:00AM  Cytori to Introduce Next-Generation Celution® Technology GlobeNewswire
May-31-17 09:00AM  Cytori and BARDA Execute $13.4 Million Contract Option for Burn Clinical Trial GlobeNewswire
May-25-17 12:38PM  ETFs with exposure to Cytori Therapeutics, Inc. : May 25, 2017 Capital Cube
May-24-17 09:11AM  Cytori Therapeutics, Inc. :CYTX-US: Earnings Analysis: Q1, 2017 By the Numbers : May 24, 2017 Capital Cube
May-23-17 08:30AM  Cytori Logs Final 48 Week Patient Follow Up Visit in Scleroderma Trial GlobeNewswire +12.50%
May-18-17 03:15PM  Edited Transcript of CYTX earnings conference call or presentation 11-May-17 9:30pm GMT Thomson Reuters StreetEvents
May-16-17 08:30AM  Cytori Provides Latest Corporate Update at the 18th Annual B. Riley & Co. Institutional Investor Conference GlobeNewswire -6.96%
May-11-17 09:21PM  Edited Transcript of CYTX earnings conference call or presentation 11-May-17 9:30pm GMT Thomson Reuters StreetEvents
06:14PM  Cytori reports 1Q loss Associated Press
04:25PM  Cytori Reports First Quarter 2017 Business and Financial Results GlobeNewswire
May-10-17 09:00AM  One Year Follow Up of Cytori Cell Therapy in Investigator Erectile Dysfunction Trial GlobeNewswire
May-05-17 07:00PM  Cytori Therapeutics Announces Inducement Grants for New Employees GlobeNewswire
Apr-27-17 04:30PM  Cytori to Webcast First Quarter Financial Results on May 11 GlobeNewswire
Apr-11-17 10:22AM  Cytori Therapeutics Stock Sliding on Offering Price Discount TheStreet.com -34.88%
09:32AM  Cytori Therapeutics' stock plunges toward record low after stock offering prices at deep discount MarketWatch
08:45AM  Cytori Announces Pricing of $9.5M Public Offering of Common Stock GlobeNewswire
07:30AM  Today's Research Reports on Biotech Stocks to Watch: Cytori Therapeutics and Geron Accesswire
Apr-10-17 04:01PM  Cytori Announces Proposed Public Offering of Common Stock GlobeNewswire +25.55%
01:58PM  Cytori Get FDA Approval for Clinical Burn Trial Investopedia
01:45PM  ETFs with exposure to Cytori Therapeutics, Inc. : April 10, 2017 Capital Cube
10:35AM  Cytori Rises on Crucial FDA Approval 24/7 Wall St.
07:00AM  Cytori Receives U.S. FDA Approval for Burn Clinical Trial Related to BARDA Contract GlobeNewswire
Apr-03-17 07:00AM  Cytori Appoints Gregg Lapointe to Board of Directors GlobeNewswire
Mar-30-17 01:04PM  CYTORI THERAPEUTICS, INC. Financials
Mar-29-17 08:30PM  ETFs with exposure to Cytori Therapeutics, Inc. : March 30, 2017 Capital Cube
08:30PM  ETFs with exposure to Cytori Therapeutics, Inc. : March 30, 2017
Mar-28-17 12:42PM  Cytori Therapeutics, Inc. :CYTX-US: Earnings Analysis: Q4, 2016 By the Numbers : March 28, 2017 Capital Cube
12:42PM  Cytori Therapeutics, Inc. :CYTX-US: Earnings Analysis: Q4, 2016 By the Numbers : March 28, 2017
10:32AM  Cytori Therapeutics, Inc. :CYTX-US: Earnings Analysis: 2016 By the Numbers : March 28, 2017
Mar-24-17 05:12PM  CYTORI THERAPEUTICS, INC. Files SEC form 10-K, Annual Report
Mar-23-17 05:07PM  Cytori reports 4Q loss Associated Press
05:02PM  CYTORI THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and
04:25PM  Cytori Reports Fourth Quarter and Full Year 2016 Business and Financial Results GlobeNewswire
Mar-17-17 07:00AM  Cytori to Webcast Fourth Quarter Financial Results on March 23rd GlobeNewswire
Mar-03-17 04:40PM  CYTORI THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement
Feb-15-17 04:30PM  CYTORI THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Completion of Acquisition o
Cytori Therapeutics, Inc., a therapeutics company, together with its subsidiaries, develops regenerative and oncologic therapies from its proprietary cell therapy and nanoparticle platforms for various medical conditions. Its lead drug candidate, ATI-0918, is a generic version of pegylated liposomal encapsulated doxorubicin, which is in Phase III clinical trial and used for various cancer types. The company's second nanomedicine drug candidate is, ATI-1123, a novel and new chemical entity, which has completed Phase I clinical trial and is a workhorse chemotherapeutic drug used for various cancers. It also sells Celution cell processing systems, StemSource cell and tissue banking systems, and surgical accessories and instrumentation to hospitals, clinics, physicians, researchers, and other customers for commercial and research purposes through a combination of a direct sales force, third-party distributors, independent sales representatives, and licensees. In addition, the company markets and sells its proprietary enzymatic reagents under the Celase and Intravase brands. It has operations in the Americas, Japan, EMEA, and the Asia Pacific. Cytori Therapeutics, Inc. was founded in 1996 and is headquartered in San Diego, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
PostFinance AG10% OwnerFeb 14Sale0.34473,831161,0084,543,086Feb 15 04:05 PM
PostFinance AG10% OwnerFeb 13Sale0.31101,71031,6525,016,917Feb 14 04:19 PM
PostFinance AG10% OwnerFeb 12Sale0.31185,27258,3245,118,627Feb 14 04:19 PM
PostFinance AG10% OwnerFeb 09Sale0.347,5522,5685,303,899Feb 12 04:07 PM
PostFinance AG10% OwnerFeb 08Sale0.34228,60378,4345,311,451Feb 12 04:07 PM
Swissquote Bank SA10% OwnerJan 11Sale0.3472,63024,7165,328,229Jan 11 12:08 PM
Swissquote Bank SA10% OwnerJan 10Sale0.3815,7966,0075,400,859Jan 11 12:08 PM
Swissquote Bank SA10% OwnerJan 09Sale0.38100,00038,3325,416,655Jan 11 12:08 PM